Evaluation of similar biotherapeutic products: Scientific and regulatory challenges  by Griffiths, Elwyn et al.
at SciVerse ScienceDirect
Biologicals 39 (2011) 249Contents lists availableBiologicals
journal homepage: www.elsevier .com/locate/bio logicalsGuest Editorial
Evaluation of similar biotherapeutic products: Scientiﬁc and regulatory challengesA 3 day workshop entitled WHO/KFDA Joint Workshop on
Implementing WHO Guidelines on Evaluating Similar Bio-
therapeutic Products was held on 24–26 August 2010 in Seoul,
Republic of Korea to consider issues relating to the implementation
and use of the WHO Guidelines on Evaluating Similar Bio-
therapeutic Products which was adopted by the WHO Expert
Committee on Biological Standardization (ECBS) in October 2009.
The workshop featured speakers from regulatory agencies from
various countries, clinical and scientiﬁc experts, representatives
from the biopharmaceutical industry andWHO. In this issue of Bio-
logicals we present 24 peer reviewedmanuscripts based on presen-
tations at the workshop, plus the introductory overviews on
pertinent issues and meeting reports of previous WHO work-
shops/consultations on WHO Guidelines on Evaluating Similar Bio-
therapeutic Products. The online published articles in this issue are
freely accessible to the public.
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